VSN16S, an agonist of the cannabinoid receptor, reduces IOP profiles and exhibits neuroprotective properties in a rat model of glaucoma (2022)
Attributed to:
Biomedical Catalyst – Drug product production, clinical support studies, and phase 1 trial of a new MS drug
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/j.1755-3768.2022.116
Publication URI: http://dx.doi.org/10.1111/j.1755-3768.2022.116
Type: Journal Article/Review
Parent Publication: Acta Ophthalmologica
Issue: S267